Your browser doesn't support javascript.
loading
Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs.
Mahtta, Dhruv; Ramsey, David J; Lee, Michelle T; Chen, Liang; Al Rifai, Mahmoud; Akeroyd, Julia M; Vaughan, Elizabeth M; Matheny, Michael E; Santo, Karla Rodrigues do Espirito; Navaneethan, Sankar D; Lavie, Carl J; Birnbaum, Yochai; Ballantyne, Christie M; Petersen, Laura A; Virani, Salim S.
Afiliação
  • Mahtta D; Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX.
  • Ramsey DJ; Health Policy, Quality & Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center Health Services Research & Development Center for Innovations in Quality, Effectiveness, and Safety, Houston, TX.
  • Lee MT; Health Policy, Quality & Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center Health Services Research & Development Center for Innovations in Quality, Effectiveness, and Safety, Houston, TX.
  • Chen L; Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX.
  • Al Rifai M; Health Policy, Quality & Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center Health Services Research & Development Center for Innovations in Quality, Effectiveness, and Safety, Houston, TX.
  • Akeroyd JM; Health Policy, Quality & Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center Health Services Research & Development Center for Innovations in Quality, Effectiveness, and Safety, Houston, TX.
  • Vaughan EM; Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX.
  • Matheny ME; Health Policy, Quality & Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center Health Services Research & Development Center for Innovations in Quality, Effectiveness, and Safety, Houston, TX.
  • Santo KRDE; Division of General Internal Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX.
  • Navaneethan SD; Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX.
  • Lavie CJ; Geriatrics Research Education and Clinical Care, Tennessee Valley Healthcare System VA, Nashville, TN.
  • Birnbaum Y; Departments of Biomedical Informatics, Biostatistics, and Medicine, Vanderbilt University Medical Center, Nashville, TN.
  • Ballantyne CM; Academic Research Organization, Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Petersen LA; Section of Nephrology and Institute of Clinical and Translational Research, Baylor College of Medicine, Houston, TX.
  • Virani SS; Section of Nephrology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX.
Diabetes Care ; 45(2): 372-380, 2022 02 01.
Article em En | MEDLINE | ID: mdl-35015080
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Veteranos / Doenças Cardiovasculares / Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose Limite: Humans Idioma: En Revista: Diabetes Care Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Veteranos / Doenças Cardiovasculares / Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose Limite: Humans Idioma: En Revista: Diabetes Care Ano de publicação: 2022 Tipo de documento: Article